Chief Accounting Officer
Skye Bioscience, Inc. (SKYE)Board Member
Skye Bioscience, Inc. (SKYE)Equibles does not estimate personal net worth.
Get an email with a short summary when Skye Bioscience, Inc. publishes a filing, an earnings call transcript or a press release.
Get SKYE alertsPunit Dhillon is recorded as Chief Accounting Officer at Skye Bioscience, Inc. (SKYE) since February 20, 2026, Board Member at Skye Bioscience, Inc. (SKYE) since January 1, 2018 and CEO at Skye Bioscience, Inc. (SKYE). The newest filing on record that lists Punit Dhillon as CEO and Board Member at Skye Bioscience, Inc. (SKYE) is dated April 16, 2026. Skye Bioscience, Inc. reported in an 8-K filed September 11, 2026 that Punit Dhillon was appointed principal financial and accounting officer, effective September 8, 2026. Skye Bioscience, Inc. reported in an 8-K filed August 14, 2026 that Punit Dhillon resigned as Chief Executive Officer, effective August 31, 2027. Skye Bioscience, Inc. reported in an 8-K filed February 20, 2026 that Punit Dhillon was appointed principal accounting officer, effective February 20, 2026. The proxy statement of Skye Bioscience, Inc. reports total compensation of $1,361,831 for Punit Dhillon in fiscal 2025, including a base salary of $610,000. Disclosed compensation is on record for 4 fiscal years. Punit Dhillon has spoken on 6 earnings calls across 1 company, most recently for Skye Bioscience, Inc. on March 10, 2026. Skye Bioscience, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Skye Bioscience, Inc. includes Lisa Anson (CEO), Paul Grayson (Chairman and Board Member), Elena Traistaru (CFO) and 7 others.
“on September 9, 2026, the Board of Directors of the Company appointed Punit Dhillon, the Company's President and Chief Executive Officer, as the Company's principal financial and accounting officer, effective as of September 8, 2026.”
“In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Dhillon (the "Dhillon Separation Agreement") pursuant to which Mr. Dhillon's last day of employment with the Company will be August 31, 2027, unless he resigns or is terminated prior to such date”
“Thank you for joining us. i'll start with what we've accomplished since our q3 update cbeyond established a potential path for namasimab alongside existing incretent therapies with additive weight loss encouraging durability and favorable tolerability at the same time we strengthen the plan around the signal with…”
“Today and during this quarter and the subsequent quarters, we're really focused on what matters most: turning the answers from our CBEYOND study into the logical next steps.”
“Today, we have most of our executive team participating in our financial results and operations update through prepared comments, or they're available to address questions during the Q&A. As we often say, we've managed the course with discipline, and we're now approaching the point where preparation becomes proof.”
“I'm here with members of our management team to review Skye's first quarter 2025 performance. I'll briefly recap our key upcoming clinical milestones and highlight our operational roadmap for the rest of 2025 before turning it over to our CSO and CFO to share more details around our preclinical data and financials.”
“We appreciate your interest in Skye, and thank you to our shareholders. Joining me is our entire executive team, and they will stay online for the Q&A portion after the prepared remarks.”
2026-02-20–present
2018-01-01–present
Last confirmed April 16, 2026
Start not stated–present
Last confirmed April 16, 2026
2026-02-20–2021-10-04
Biotechnology · Healthcare
CEO, Chief Accounting Officer, Board Member
2018-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Skye Bioscience, Inc. (SKYE) | Chief Executive Officer | $610,000 | $1,361,831 |
| 2024 | Skye Bioscience, Inc. (SKYE) | Chief Executive Officer | $458,333 | $6,139,625 |
| 2023 | Skye Bioscience, Inc. (SKYE) | Chief Executive Officer | $450,000 | $1,807,338 |
| 2022 | Skye Bioscience, Inc. (SKYE) | CEO | $432,577 | $668,481 |
